Tauklarify imaging is a brain PET scan that finds tau tangles in adults with cognitive impairment evaluated for Alzheimer's. Tau tangles are clumps of tau protein that damage brain cells and track with Alzheimer's decline. It was approved by federal regulators in 2026 for this use, according to the FDA approval notice.
A primary care visit is often where families decide whether added testing will change care. This scan does not replace memory testing, lab work, or a clinical exam. It adds one piece of biology that can clarify next steps.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does the scan show?
- Who is it for in primary care?
- How do patients get it, and what about cost?
- What should you ask after the scan?
What does the scan show?
Tauklarify uses florquinitau F 18 injection to bind clumped tau during PET imaging. It can show tangles even when disease is limited to the medial temporal lobe, according to the Lantheus announcement. That area handles memory and is often affected early.
Reader agreement was mixed in the approval studies. Positive agreement ranged from 68 percent to 88 percent, while negative agreement ranged from 93 percent to 99 percent. A clear negative result is therefore more consistent across readers than a positive result.
Who is it for in primary care?
The intended patient is an adult with noticed thinking or memory problems who is being evaluated for Alzheimer's. The scan is meant to identify tau tangle pathology in that evaluation, not to screen healthy adults.
It has clear limits. Safety and effectiveness are not established for non-Alzheimer tau disorders, and performance may be lower earlier in the disease process. A negative scan does not necessarily rule out tau, and a positive scan alone does not prove Alzheimer's tissue disease, so uncertain results need added testing.
How do patients get it, and what about cost?
Access in 2026 runs through Enigma Biomedical USA, with distribution and reporting through Cerveau Technologies. Lantheus has said it is reviewing wider commercial availability, so primary care offices may need to refer to a memory clinic or PET center.
Ask about coverage before scheduling. Medicare no longer uses the old national amyloid-PET evidence-development rule and one-per-lifetime limit, leaving decisions to regional contractors, according to the NeurologyLive report. Amyloid PET self-pay has been cited above 3,000 dollars, so request prior authorization, a written cost estimate, and the billing code for tau PET.
- Ask whether your regional Medicare plan or private insurer covers tau PET
- Ask for referral sites, scheduling wait, and travel needs
- Ask what records, cognitive scores, and prior scans to bring
What should you ask after the scan?
Bring a list of follow-up questions to the results visit. Ask what a positive, negative, or unclear read means for diagnosis, medicines, safety planning, and need for spinal fluid, blood, or amyloid tests. Ask when to repeat cognitive testing and when to seek specialist input.
Also review practical risks. The recommended dose is one 185-MBq intravenous bolus, with headache, nausea, injection-site reaction, dizziness, and abdominal discomfort reported at low rates plus added radiation exposure, according to the Pharmacy Times summary. Tell the team about pregnancy, breastfeeding, prior contrast reactions, and recent imaging.
- What tangle pattern was seen, and how certain is the read?
- Does the result point toward Alzheimer's or another cause?
- What daily supports, driving plan, work notes, or trial options fit now?
You Might Also Like
- The Third FDA-Cleared Alzheimer’s Blood Biomarker Test in 2026: Access, Cost, and Follow-Up Questions for Primary Care Patients
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: Access, Cost, and Follow-Up Questions for Primary Care Patients
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: Access, Cost, and Follow-Up Questions for Primary Care Patients
